We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Novel Rapid Lateral Flow Immunoassay Can Function as `Suitcase Laboratory` for On-Site Detection of COVID-19

By LabMedica International staff writers
Posted on 11 Dec 2020
Print article
Image: The principle of HC-FIA (Photo courtesy of SIBET)
Image: The principle of HC-FIA (Photo courtesy of SIBET)
Scientists have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA) to fulfill the need for rapid and accurate nucleic acid detection at the point of care.

The use of the monoclonal antibody S9.6 is the distinctive feature of this process developed by scientists from the Suzhou Institute of Biomedical Engineering and Technology (Suzhou, China). The process recognizes DNA-RNA double-stranded hybrids and enables the conversion of nucleic acid testing into immunofluorescence on a simple lateral flow dipstick. The whole test procedure involves two steps, namely hybridization and immunofluorescence analysis, and it can be finished in less than an hour.

The process uses optimized DNA probes to target the conserved open reading frame 1ab, envelope protein and the nucleocapsid regions of the SARS-CoV-2 genome derived from clinical throat swab samples. It can achieve a limit of detection of 500 copies/mL, comparable to commercial kits based on real-time quantitative polymerase chain reaction (qPCR). In addition, no significant cross-reaction has been found between the SARS-CoV-2 probes and 55 common pathogens. The performance of the HC-FIA detection reagent is free of interference by hemoglobin, mucin and various possible drugs that might exist in clinical samples. The assay and test kit can also be adapted for the detection of other viral RNA.

The HC-FIA process was supported by a multi-hospital randomized double-blind trial involving 734 samples. The current research not only represents proof-of-concept, but also has resulted in development of a commercial test kit for the diagnosis of SARS-CoV-2. The test kit was recently approved by the National Medical Products Administration and received European Conformity certification. The test kit requires little in terms of equipment and professional personnel to confirm infection. It can function as a "suitcase laboratory" and thus be used as an on-site detection method for outpatient departments, emergency departments, customs and grassroots disease control.

"We are confident that the HC-FIA test is capable of serving as a sure safeguard in containing the epidemic through reducing community spread and imported cases, especially in developing countries," said WANG Daming, lead researcher of the study.

Related Links:
Suzhou Institute of Biomedical Engineering and Technology

Gold Supplier
Sample Transport
VACUETTE Transport Line
Immunoassay Reader
ichroma II
Flu + SARS Antigen Test
Sofia 2 Flu + SARS Antigen FIA
COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.